SCHEMBL4472290

SCHEMBL4472290

Cc1csc(N2CCC2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.54
MEN1 O00255 2/20 0.48
SMN1; SMN2 Q16637 4/20 0.46
AR P10275 3/20 0.46
LMNA P02545 2/20 0.46
TP53 P04637 1/20 0.46
ALOX15 P16050 1/20 0.46
HSD17B10 Q99714 1/20 0.46
HRH3 Q9Y5N1 2/20 0.46
DPP4 P27487 1/20 0.46
OGA O60502 2/20 0.45
RAB9A P51151 1/20 0.44
POLB P06746 2/20 0.41
NOS1 P29475 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
BLM P54132 1/20 0.40
KMT2A Q03164 1/20 0.40
ESR2 Q92731 1/20 0.40
PIK3CG P48736 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3511935 0.96 L3MBTL1 (0.54) L3MBTL1MEN1SMN1; SMN2ARLMNA
SCHEMBL4469579 0.94 SMN1; SMN2 (0.53) L3MBTL1MEN1SMN1; SMN2ARLMNA
SCHEMBL3551633 0.89 ALDH1A1 (0.49) L3MBTL1MEN1SMN1; SMN2ARLMNA
SCHEMBL9794796 0.86 L3MBTL1 (0.46) L3MBTL1MEN1SMN1; SMN2ARLMNA
SCHEMBL9794803 0.84 BAZ2A (0.48) L3MBTL1MEN1SMN1; SMN2HRH3DPP4
SCHEMBL1713003 0.84 L3MBTL1 (0.47) L3MBTL1MEN1SMN1; SMN2ARLMNA
SCHEMBL9794819 0.84 L3MBTL1 (0.47) L3MBTL1MEN1SMN1; SMN2ARLMNA
SCHEMBL6929063 0.84 ALDH1A1 (0.54) L3MBTL1MEN1SMN1; SMN2LMNAHRH3
SCHEMBL4463690 0.82 LMNA (0.68) MEN1SMN1; SMN2ARLMNARAB9A
SCHEMBL2228747 0.82 BAZ2A (0.49) L3MBTL1MEN1SMN1; SMN2LMNAHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550486-B2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-23 US disclosed
US-20080132523-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2008-06-05 US disclosed
US-7351720-B2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2008-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132523-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ACKR3, CCR7, CCR2 L3MBTL1 4872/4885MEN1 4524/4885SMN1; SMN2 4441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.